Improving the Efficiency of Antimicrobial Stewardship Action in Acute Care Facilities.

Autor: Heil EL; Department of Practice, Sciences and Health Outcomes Research, School of Pharmacy, University of Maryland, Baltimore, Maryland, USA., Justo JA; Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.; Department of Pharmacy, Prisma Health Richland Hospital, Columbia, South Carolina, USA., Bork JT; Division of Infectious Diseases, Institute of Human Virology, Department of Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.; Veterans Affairs (VA) Maryland Health Care System, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2023 Aug 01; Vol. 10 (9), pp. ofad412. Date of Electronic Publication: 2023 Aug 01 (Print Publication: 2023).
DOI: 10.1093/ofid/ofad412
Abstrakt: Inpatient antimicrobial stewardship (AS) programs are quality improvement programs tasked with improving antibiotic practices by augmenting frontline providers' antibiotic prescription. Prospective audit and feedback (PAF) and preauthorization (PRA) are essential activities in the hospital that can be resource intensive for AS teams. Improving efficiency in AS activities is needed when there are limited resources or when programs are looking to expand tasks beyond PAF and PRA, such as broad education or guideline development. Guidance on the creation and maintenance of alerts for the purpose of PAF reviews, modifications of antibiotic restrictions for PRA polices, and overall initiative prioritization strategies are reviewed. In addition, daily prioritization tools, such as the tiered approach, scoring systems, and regression modeling, are available for stewards to prioritize their daily workflow. Using these tools and guidance, AS programs can be productive and impactful in the face of resource limitation or competing priorities in the hospital.
Competing Interests: Potential conflicts of interest. J. J. receives payment for lectures from bioMérieux and Spero Therapeutics and participates in Merck, Entasis Therapeutics, Shionogi, and Gilead Sciences advisory boards. E. L. H. receives consulting fees from Wolters-Kluwer/Lexi-Comp. J. T. B. reports no potential conflicts.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje